Does a low omega-3 index indicate reduced EPA and DHA incorporation and higher inflammatory and cardiovascular risk?

The omega-3 index, which measures the percentage of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in red blood cell (RBC) membranes, integrates a 2- to 4-month history of fatty acid status. A low index directly represents reduced membrane incorporation and serves as a powerful predictor of adverse clinical outcomes.

Cardiovascular risk and clinical evidence

• Clinical data define three distinct risk zones: high risk (<4%), intermediate risk (4–8%), and low risk (>8%).
• Individuals with a high-risk index (<4%) experience a doubled hazard ratio for total mortality post-myocardial infarction compared to those with an index ≥4%.
• Achieving a high index (≥11%) or securing a ≥5% absolute increase in the index through therapy is associated with a 54% reduction in long-term major adverse cardiovascular events (MACE).

Inflammatory and cellular mechanisms

• Reduced incorporation of EPA and DHA directly impairs the physical properties of erythrocytes, resulting in decreased membrane fluidity and deformability.
• Low omega-3 status is inversely correlated with systemic inflammatory markers, driving elevated levels of interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP).
• Elevated IL-6 promotes hepatic CRP production and actively accelerates atherosclerotic plaque progression, linking membrane fatty acid depletion directly to heightened cardiovascular risk.

Bottom line

• Bottom line: An omega-3 index below 4% is a validated marker of depleted erythrocyte membrane EPA and DHA that promotes systemic inflammation via elevated IL-6 and hsCRP, significantly increasing cardiovascular and mortality risks; conversely, optimizing this index to ≥8% offers robust cardioprotection.